SCHEMBL22223491

SCHEMBL22223491

CC(C)(C)OC(=O)C(CNC(=O)CCCCCN1C(=O)C=CC1=O)NC(=O)CCCCCCCCCCCCCCCC(C)(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 1/20 0.37
▸ PTGS1 P23219 7/20 0.37
▸ PTGS2 P35354 7/20 0.37
▸ SMN1; SMN2 Q16637 5/20 0.33
▸ HTT P42858 3/20 0.33
▸ HPGD P15428 2/20 0.33
▸ ALDH1A1 P00352 5/20 0.32
▸ MGLL Q99685 4/20 0.32
▸ FAAH O00519 3/20 0.32
▸ MAPT P10636 3/20 0.32
▸ NPSR1 Q6W5P4 3/20 0.32
▸ LMNA P02545 2/20 0.32
▸ PKM P14618 2/20 0.32
▸ HSP90AA1 P07900 1/20 0.32
▸ TLR9 Q9NR96 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ XBP1 P17861 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22223484 0.81 PTGS1 (0.40) AKT1PTGS1PTGS2SMN1; SMN2HTT
SCHEMBL24589079 0.81 PTGS1 (0.43) AKT1PTGS1PTGS2SMN1; SMN2HTT
SCHEMBL22223433 0.79 AKT1 (0.35) AKT1PTGS1PTGS2SMN1; SMN2HTT
SCHEMBL28501353 0.77 PTGS1 (0.47) AKT1PTGS1PTGS2SMN1; SMN2HTT
SCHEMBL27292160 0.77 PTGS1 (0.49) PTGS1PTGS2SMN1; SMN2HTTHPGD
SCHEMBL24864492 0.77 PTGS1 (0.49) PTGS1PTGS2SMN1; SMN2HTTHPGD
SCHEMBL22223294 0.75 DNM1 (0.38) FAAHMAPK1HDAC1HDAC6
SCHEMBL17196272 0.74 AKT1 (0.55) AKT1SMN1; SMN2ALDH1A1MAPTHDAC3
SCHEMBL22045035 0.74 AKT1 (0.48) AKT1PTGS1PTGS2NPSR1HDAC3
SCHEMBL27335505 0.73 PTGS1 (0.50) AKT1PTGS1PTGS2SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204976-A1 RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT 2022-06-30 — — US disclosed
WO-2020146521-A2 RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE Arrowhead Pharmaceuticals, Inc. (US) 2020-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204976-A1 RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use EPAS1, HIF1AN, HIF1A AKT1 631/4885PTGS1 1489/4885PTGS2 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback